文献速递妇科

应对子宫肌瘤研究中的异质性结局:行动呼吁

Addressing heterogenous outcomes in uterine fibroid research: a call to action.
PubMed 文献 · Am J Obstet Gynecol · 2020-03-19

子宫肌瘤是女性最常见的良性盆腔肿瘤,可导致月经过多、盆腔疼痛、生殖并发症及压迫症状。现有药物、手术和放射治疗的比较效果评价发现,由于临床研究采用异质性结局和测量工具,缺乏高质量数据指导治疗决策。本文呼吁开发并使用核心结局集,以捕捉晚期和上市后治疗试验中最相关、对患者重要的结局。

要点

  • 子宫肌瘤研究结局异质性阻碍治疗决策的高质量证据生成
  • 建议由多利益相关方制定核心结局集
  • 核心结局集应涵盖患者重要结局并用于晚期及上市后试验

核心结论

  • 呼吁开发并采用核心结局集,以解决子宫肌瘤研究中结局异质性问题,确保跨研究一致且透明的结局报告。

研究设计与样本

  • 本文为行动呼吁类文章,未报告系统检索或样本量。

主要发现

  • 子宫肌瘤是女性最常见良性盆腔肿瘤,可致月经过多、盆腔疼痛、生殖并发症及压迫症状。
  • 多数子宫肌瘤无症状,但症状者可显著影响生活质量和日常功能。
  • 现有药物、手术和放射治疗的比较效果评价发现缺乏高质量数据指导治疗决策,部分源于临床研究使用异质性结局和工具。

临床怎么用

  • 在晚期和上市后治疗试验中采用核心结局集,以一致报告患者重要结局。
  • 核心结局集应由包括关键医疗决策者在内的多元多利益相关方小组制定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Uterine fibroid tumors are the most common benign pelvic tumors in women, with complications that include heavy menstrual bleeding, pelvic pain, reproductive complications, and bulk-related symptoms. Although the majority of uterine fibroid tumors are asymptomatic, those women who experience symptoms can experience substantial burdens on quality of life and daily functioning. Comparative effectiveness reviews of available medical, surgical, and radiologic treatments have found that a lack of high-quality data to inform treatment decisions is, in part, due to the use of heterogeneous outcomes and instruments in clinical studies. With multiple new interventions emerging, this call-to-action encourages the development and use of a core outcome set that will capture the most relevant, patient-important outcomes in late-phase and after-marketing therapeutic trials for uterine fibroid tumors. The core outcome set should be developed by a diverse, multistakeholder group comprised of key healthcare decision-makers. Development and uptake of a core outcome set ensures that a consistent, collaboratively vetted set of outcomes will be accessible across different studies and promotes transparency for innovators who seek to anticipate the evidence needs of patients, providers, payers, regulators, and other stakeholders.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Tran AP, Al Naber J, Tambor ES, et al. Addressing heterogenous outcomes in uterine fibroid research: a call to action. Am J Obstet Gynecol. 2020. PMID: 32199924. doi:10.1016/j.ajog.2020.03.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。